Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Gene expression profile of pediatric AML

ABSTRACT: Gene expression data were obtained from 130 pediatric AML patients who were enrolled on the AML99 study conducted by the Japanese Childhood AML Cooperative Study Group.

ORGANISM(S): Homo sapiens

PROVIDER: GSE35784 | GEO | 2013/04/01

SECONDARY ACCESSION(S): PRJNA152177

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Gene expression profile of pediatric AML

Project description:Gene expression data were obtained from 130 pediatric AML patients who were enrolled on the AML99 study conducted by the Japanese Childhood AML Cooperative Study Group. RNA samples obtained at the time of diagnosis were analyzed using GeneChip Human Genome U133 plus 2.0 array (Affymetrix).

2013-04-01 | E-GEOD-35784 | biostudies-arrayexpress

Genomic analysis of pediatric AML by whole transcriptome sequencing [pediatric AML patients]

Project description:Pediatric AML is an aggressive hematological malignancy associated with distinctive genomic features. We employed RNA-seq to study fusion genes and clinically relevant gene expression patterns in pediatric AML patients.

2023-05-02 | GSE222814 | GEO

Transcription profiling of acute myeloid leukemia FLT3 wild type and mutants in childhood AML samples from the Pediatric Oncology Group Study 9421

Project description:This data set was used to study FLT3 wild type and mutants in childhood AML samples from the Pediatric Oncology Group Study 9421. The data set was analyzed and published in the Journal Blood in 2002 by Lacayo NJ et al.

2005-11-03 | E-SMDB-2850 | biostudies-arrayexpress

Gene expression profiling of pediatric myelodysplastic syndrome (MDS) characterizes disease subtype and time to progression into acute myeloid leukemia (AML)

Project description:Identification of relevant subgroups in childhood MDS patients by gene expression analysis and gene involve in progression into AML Class comparison between different subgroups of pediatric MDS (class risk, classification subtype)

2012-02-29 | E-GEOD-29326 | biostudies-arrayexpress

ChIPseq for pediatric AML patients

Project description:Purpose: Next-generation sequencing (NGS) has revolutionized systems-based analysis of cellular pathways. The goals of this study are to explore ChIPseq results for pediatric AML patients.

2022-07-20 | GSE188605 | GEO

Genomic analysis of pediatric AML by whole transcriptome sequencing [pediatric AML patients]

Project description:Genomic analysis of pediatric AML by whole transcriptome sequencing [pediatric AML patients]

| PRJNA923607 | ENA

ChIPseq for pediatric AML patients

Project description:ChIPseq for pediatric AML patients

| PRJNA779619 | ENA

Affymetrix U133A array data for 111 pediatric acute myeloid leukemia (AML) samples at diagnosis

Project description:Genome-wide profiling of Copy Number Alterations (CNA) and Loss of Heterozygosity (LOH), gene expression and resequencing of pediatric AML This study characterizes CNA and LOH, gene expression and gene sequence mutations in a representative cross-section through subtypes of pediatric AML. Keywords: Affymetrix arrays were performed according to the maufacturers directions on DNA extracted from cryopreserved diagnostic bone marrow or peripheral blood samples. Samples with less than 80% blasts were flow sorted prior to DNA extraction 111 pediatric AML samples were studied using the Affymetrix U133A array.

2010-01-03 | E-GEOD-14471 | biostudies-arrayexpress

Expression data from pediatric AML patients

Project description:Pediatric acute myeloid leukemia (AML) is a heterogeneous disease characterized by non-random genetic aberrations related to outcome. Detecting these aberrations however still lead to failures or false negative results. Therefore, we focused on the potential of gene expression profiles (GEP) to classify pediatric AML. Gene expression microarray data of 237 children with AML were generated and cases were split into a discovery cohort (n=157) and an independent validation cohort (n=80). Next, a double-loop cross validation approach was used to generate a subtype-predictive GEP in the discovery cohort which was then tested for its true predictive value in the independent validation cohort. 237 bone marrow and peripheral blood samples were collected at diagnosis and frozen. They were later thawed and hybridized to Affymetrix U133 Plus 2.0 arrays.

2010-10-21 | E-GEOD-17855 | biostudies-arrayexpress

microRNA profiling in pediatric AML

Project description:MicroRNAs (miRNAs) play a pivotal role in the regulation of hematopoiesis and development of leukemia. Great interest emerged in modulating miRNA expression for therapeutic purposes. In order to identify miRNAs, which specifically suppress leukemic growth of AML with t(8;21), inv(16) or MLL-rearrangement by inducing differentiation, we conducted a miRNA expression profiling in a cohort of 90 cytogenetically characterized, de novo pediatric AML cases. Four miRNAs, specifically downregulated in MLL-rearranged, t(8;21) or inv(16) AMLs, were characterized by their tumor suppressive properties in cell lines representing those respective cytogenetic groups. Among those, forced expression of miR-9 reduced leukemic growth and induced monocytic differentiation of t(8;21) AML cell lines in vitro and in vivo. The tumor suppressive functions of miR-9 were specifically restricted to AML cell lines and primary leukemic blasts with t(8;21). On the other hand, these functions were not evident in AML blasts from patients with MLL-rearrangements. We showed that miR-9 exerts its effects through the cooperation with let-7 to repress the oncogenic LIN28B/HMGA2 axis. Thus, miR-9 is a tumor suppressor-miR which acts in a stringent cell context-dependent manner. In order to identify miRNAs, which specifically suppress leukemic growth of AML with t(8;21) (n=21), inv(16) (n=17) or MLL-rearrangement (n=35) by inducing differentiation, we conducted a miRNA expression profiling in a cohort of 90 cytogenetically characterized, de novo pediatric AML cases, which also included 12 t(15;17) and 5 t(7;12) samples.

2014-01-01 | E-GEOD-52541 | biostudies-arrayexpress

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data